RxDoctor Payments Data

Anne Park

Nurse Practitioner · Las Vegas, NVNPI 1417650896

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Gilead at 25.2% of the total. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,736in general payments, 2019–2025

Across 188 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • AstraZeneca$715
  • AbbVie$499
  • Bayer$382
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$375
  • Amgen$366
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,736 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$49,120
JardianceEmpagliflozin20$25,735
EliquisApixaban13$14,789
FarxigaDapagliflozin Propanediol13$11,357
Albuterol Sulfate HfaAlbuterol Sulfate75$2,251
Wixela InhubFluticasone Propion/Salmeterol14$1,606
Atorvastatin Calcium195$1,477
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,304
Lidocaine11$1,069
Ezetimibe17$802
Amlodipine Besylate147$797
Levothyroxine Sodium71$714
Losartan Potassium104$712
Metformin Hcl101$677
Lisinopril124$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$151$49,12038 claims
Boehringer IngelheimJardiance$39$25,73520 claims
PfizerEliquis$176$14,78913 claims
AstraZenecaFarxiga$715$11,35713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →